The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease
- PMID: 32692069
- DOI: 10.1097/DCR.0000000000001716
The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease
References
-
- Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JBPrevalence of inflammatory bowel disease among adults aged ≥18 years – United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:1166–1169.
-
- Colombel JF, Sandborn WJ, Rutgeerts P, et al.Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
-
- Hanauer SB, Feagan BG, Lichtenstein GR, et alACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
-
- Hanauer SB, Sandborn WJ, Rutgeerts P, et al.Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333.
-
- Sandborn WJ, Feagan BG, Stoinov S, et alPRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–238.